Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.42 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.35 |
| ▸ | TAB1 | Q15750 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.32 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.31 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.31 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.31 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.31 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.31 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14485246 | 1.00 | APP (0.42) | APPMAP3K7TAB1KDM4EENPP2 | |
| SCHEMBL31667122 | 1.00 | APP (0.42) | APPMAP3K7TAB1KDM4EENPP2 | |
| SCHEMBL10383610 | 0.84 | KDM4E (0.40) | MAP3K7TAB1KDM4EENPP2HDAC3 | |
| SCHEMBL11043872 | 0.78 | APP (0.42) | APPNFE2L2 | |
| SCHEMBL11043873 | 0.78 | APP (0.42) | APPNFE2L2 | |
| SCHEMBL10454309 | 0.78 | APP (0.57) | APPTRPA1NFE2L2 | |
| SCHEMBL8718543 | 0.74 | LMNA (0.56) | MAP3K7TAB1KDM4EENPP2HDAC3 | |
| SCHEMBL16420002 | 0.74 | TSHR (0.41) | KDM4EENPP2 | |
| SCHEMBL21457575 | 0.74 | HSD11B1 (0.48) | KDM4EENPP2 | |
| SCHEMBL2045820 | 0.74 | TRPA1 (0.52) | KDM4ETRPA1NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140135327-A1 | N- (2 -AMINOPHENYL) BENZAMIDE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2014-05-15 | — | — | US | disclosed |
| US-20140135327-A1 | N- (2 -AMINOPHENYL) BENZAMIDE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2014-05-15 | — | — | US | disclosed |
| US-20140135327-A1 | N- (2 -AMINOPHENYL) BENZAMIDE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2014-05-15 | — | — | US | disclosed |
| EP-2078029-B1 | ENANTIOMERICALLY PURE PHOSPHOINDOLE AS HIV INHIBITOR | IDENIX PHARMACEUTICALS INC (US) | 2014-05-14 | — | — | EP | disclosed |
| EP-2729450-A1 | N- (2 -AMINOPHENYL) BENZAMIDE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | Cancer Research Technology Ltd (GB) | 2014-05-14 | — | — | EP | disclosed |
| US-8486991-B2 | Enantiomerically pure phosphoindoles as HIV inhibitors | IDENIX PHARMACEUTICALS, INC. (US) | 2013-07-16 | — | — | US | disclosed |
| WO-2013005049-A1 | N- (2 -AMINOPHENYL) BENZAMIDE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2013-01-10 | — | — | WO | disclosed |
| US-20110257129-A1 | ENANTIOMERICALLY PURE PHOSPHOINDOLES AS HIV INHIBITORS | IDENIX PHARMACEUTICALS, INC. | 2011-10-20 | — | — | US | disclosed |
| US-7960428-B2 | (2-carbamoyl-5-chloro-1H-indol-3-yl)-[3-((E)-2-cyano-vinyl)-5-methyl-phenyl]-(S)-phosphinic acid methyl ester; Flaviviruses; bioavailability; pharmacokinetics | IDENIX PHARMACEUTICALS, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| CN-101627044-A | Phosphoindoles as the enantiomer-pure of hiv inhibitor | IDENIX PHARMACEUTICALS INC | 2010-01-13 | — | — | CN | disclosed |
| EP-2078029-A2 | ENANTIOMERICALLY PURE PHOSPHOINDOLES AS HIV INHIBITORS | IDENIX Pharmaceuticals, Inc. (US) | 2009-07-15 | — | — | EP | disclosed |
| US-20080213217-A1 | Enantiomerically pure phosphoindoles as HIV inhibitors | IDENIX PHARMACEUTICALS, INC. | 2008-09-04 | — | — | US | disclosed |
| WO-2008042240-A9 | ENANTIOMERICALLY PURE PHOSPHOINDOLES AS HIV INHIBITORS | IDENIX PHARMACEUTICALS INC (US) | 2008-08-07 | — | — | WO | disclosed |
| WO-2008042240-A2 | ENANTIOMERICALLY PURE PHOSPHOINDOLES AS HIV INHIBITORS | IDENIX PHARMACEUTICALS, INC. (US) | 2008-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140135327-A1 | N- (2 -AMINOPHENYL) BENZAMIDE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | HDAC5, HDAC2, HDAC1 | APP 4730/4885MAP3K7 2391/4885TAB1 769/4885 |
| US-20110257129-A1 | ENANTIOMERICALLY PURE PHOSPHOINDOLES AS HIV INHIBITORS | DUSP3, PNP, PPP5C | APP 2145/4885MAP3K7 855/4885TAB1 2248/4885 |
| US-20080213217-A1 | Enantiomerically pure phosphoindoles as HIV inhibitors | DUSP3, PNP, PPP5C | APP 2145/4885MAP3K7 855/4885TAB1 2248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.